Trial site
Charles Retina Institute
Germantown, Tennessee 38138, United StatesNot linked to an institution yet
- 13running trials
- 16closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 27 trials
- Phase 13 trials
- Phase 43 trials
- Phase 1/22 trials
- Phase 2/31 trial
- Status
- Completed13 trials
- Active, not recruiting8 trials
- Recruiting3 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Withdrawn1 trial
- Lead sponsor
- Hoffmann-La Roche5 trials
- Genentech, Inc.4 trials
- AbbVie2 trials
- EyePoint Pharmaceuticals, Inc.2 trials
- Kodiak Sciences Inc2 trials
- and 13 more
Running trials
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522· Phase 1· Genentech, Inc.· Source
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225· Phase 2/3· EyeBiotech Ltd.· Source
Contact: Study Coordinator
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Not yet recruiting
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
NCT06470373· Phase 3· Rophibio, Inc.· Source
Contact: Molly Scott
Recruiting
Data Gathering for A10900
NCT07149740· Optos, PLC· Source
Contact: Molly Scott
Active, not recruiting
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048· Phase 4· Hoffmann-La Roche· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368· Phase 3· Kodiak Sciences Inc· Source
Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854· Phase 1· Genentech, Inc.· Source
Active, not recruiting
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251· Phase 4· Genentech, Inc.· Source
Enrolling by invitation
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801· Phase 2· AbbVie· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Withdrawn
UNITY VCS Vitreoretinal Surgery
NCT07054281· Alcon Research· Source
Terminated
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06961370· Phase 1· Hoffmann-La Roche· Source
Completed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
NCT06270836· Phase 3· Kodiak Sciences Inc· Source
Completed
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
NCT06172257· Phase 3· Oculis· Source
Completed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source
Completed
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922· Phase 1/2· Genentech, Inc.· Source
Completed
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
NCT05447650· i-Lumen Scientific, Inc.· Source
Completed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537· Phase 2· Novartis Pharmaceuticals· Source
Completed
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
NCT04708145· Phase 4· Greater Houston Retina Research· Source
Completed
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· Phase 3· Hoffmann-La Roche· Source
Completed
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source
Completed
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
NCT04832724· Phase 2· AbbVie· Source
Completed
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
NCT04567303· Phase 1/2· Hoffmann-La Roche· Source
Terminated
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
NCT04566445· Phase 2· Gyroscope Therapeutics Limited· Source
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251· Phase 3· Hoffmann-La Roche· Source
Report an error